Books > Medicine > Clinical & internal medicine > Cardiovascular medicine
|
Buy Now
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents - Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 (Paperback, Softcover reprint of the original 1st ed. 1989)
Loot Price: R5,710
Discovery Miles 57 100
|
|
Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents - Proceedings of the Ninth Annual Symposium on New Drugs & Devices, October 27 & 28, 1988 (Paperback, Softcover reprint of the original 1st ed. 1989)
Series: Developments in Cardiovascular Medicine, 100
Expected to ship within 10 - 15 working days
|
The Symposium on New Drugs provides a forum for academic
investigators, research and development personnel from the
pharmaceutical industry and members of the Food and Drug
Administration to discuss important clinical research issues. The
Ninth Annual symposium on New Drugs addressed the problem of
determining the risk versus benefit for use of three important
classes of cardiovascular agents: thrombolytic, antiarrhythmic, and
hypolipidemic agents. The use of thrombolytic agents has become one
of the major advances in clinical intensive cardiologic care in the
1980s. While the lysis of clot(s) obstructing a major coronary
artery should reverse or prevent the damage of acute myocardial
ischemia and infarction, one must carefully consider the potential
risks of such agents in regards to their potential benefits. The
time when a thrombolytic agent should be administered to maximize
benefit as well as how one defines a dose response relationship
using intravenous critical care medicines were discussed as
important clinical trial issues. The benefit versus risk data on
currently available thrombolytic agents was reviewed and the
potential roles for adjunctive agents addressed. Overall strategies
regarding post- x thrombolytic care and relationships to sudden
cardiac death were also detailed. The panel discussion sections
provided a comprehensive view of the current thinking of the
various participating groups in this symposium. Sudden cardiac
death remains the number one cause of mortality in western
industrialized societies.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.